Marketing

  • Two prescription drug cartons stand side by side on a counter, each bearing the word Wegovy.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    CMS sets 2027 Medicare prices for Wegovy, Trelegy and 13 other drugs

    The second round of negotiations cuts spending an aggregate 44% over 2024 list prices as the federal government extends restraints over more medicines.

    By • Nov. 26, 2025
  • Location of Delaware Court of Chancery in Wilmington
    Image attribution tooltip
    Mark Makela via Getty Images
    Image attribution tooltip

    GSK, Anaptysbio sue each other over Jemperli revenue

    As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding development of the cancer immunotherapy.

    By • Nov. 21, 2025
  • A stylized illustration of a pill breaking apart into smaller pills. Explore the Trendline➔
    Image attribution tooltip
    Brian Tucker / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Trendline

    Commercialization

    New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

    By BioPharma Dive staff
  • FDA
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    With new approvals, Regeneron’s higher-dose Eylea gets more competitive

    Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.

    By Kristin Jensen • Nov. 20, 2025
  • Image attribution tooltip
    Jonathan Gardner/BioPharma Dive
    Image attribution tooltip

    Agios shares fall on mixed sickle cell results for blood disease drug

    Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its commercial outlook and the company’s reinvention as a rare disease specialist.

    By • Nov. 19, 2025
  • David Ricks, CEO of Eli Lilly, speaks alongside U.S. President Donald Trump, administration officials and fellow pharmaceutical executives on November 06, 2025 in Washington, DC.
    Image attribution tooltip
    Andrew Harnik via Getty Images
    Image attribution tooltip
    Trump administration

    Novo, Lilly cut deal with Trump to lower prices of obesity drugs

    The agreement will make Wegovy and Zepbound available to some Medicare enrollees for $245 per month, and starter doses of pill versions, once approved, for $149 monthly.

    By • Updated Nov. 7, 2025
  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Vertex’s new pain, blood disorder drugs miss Wall Street expectations

    While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear revenue misses,” wrote a Raymond James analyst.

    By • Nov. 4, 2025
  • women using health app on phone
    Image attribution tooltip
    Permission granted by Aptar Digital Health
    Image attribution tooltip
    Sponsored by Aptar Digital Health

    4 must-have capabilities in a digital health partner in the era of AI

    Unlock the 4 must-have traits that make digital health partners game-changers in pharma.

    Nov. 3, 2025
  • man in a dark blue suit speaks in the oval office
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    FDA, aiming to lower drug costs, moves to speed approval of biosimilars

    The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help developers bring them to market more quickly and cheaply. 

    By • Oct. 29, 2025
  • Glucagon-like peptide 1 (GLP1, 7-36) molecule The glucagon like peptide-1 receptor has a strong effect on the management of type 2 diabetes mellitus.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly aligns with Walmart in bid to broaden access to discounted Zepbound

    The deal, which enables patients to pick up orders placed through Lilly’s online channel at Walmart pharmacies, is the latest move by the company to expand its direct-to-consumer services. 

    By • Oct. 29, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Iambic partners with Jazz; Merck breaks ground on $3B plant

    The biotechs will assess a combination of two drugs against HER2-positive breast cancer. Elsewhere, Merck unveiled the latest piece of its more than $70 billion domestic manufacturing investment.

    By BioPharma Dive staff • Oct. 21, 2025
  • Close-up view of the Novo Nordisk logo mounted on the exterior wall of a building. The logo features a stylized blue Apis bull with a sun disk above its head, symbolizing the company's identity. The background shows a tan brick wall and part of a leafless tree in the foreground under a clear blue sky."
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Novo’s main shareholder pushes out more than half of company’s board

    The Novo Foundation chair said the current board of the Wegovy maker, which is already dealing with layoffs and a CEO change, was too slow to react to obesity market shifts.

    By • Oct. 21, 2025
  • Mark Cuban at HLTH
    Image attribution tooltip
    Susanna Vogel/BioPharma Dive
    Image attribution tooltip

    Mark Cuban says Cost Plus Drugs will partner with TrumpRx

    Cost Plus Drugs is sharing pricing data with TrumpRx, the administration’s new direct-to-consumer prescription drug website set to launch next year.

    By Susanna Vogel • Oct. 20, 2025
  • A micrograph of a myeloma neoplasm in a bone marrow biopsy.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    J&J claims success in study testing earlier Tecvayli use in multiple myeloma

    The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to later-line settings for the persistent blood cancer.

    By • Oct. 16, 2025
  • Side view portrait of doctor and patient talking in a clinic setting.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Deep Dive

    AI could transform healthcare. Can safety-net providers keep up?

    Implementing artificial intelligence requires significant human labor and technical expertise, threatening to create a digital divide between highly resourced health systems and safety-net providers.

    By Emily Olsen • Oct. 3, 2025
  • The exterior of Amgen's office building in South San Francisco, with a sculpted company sign in the foreground and leafless trees on a grassy lawn.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Amgen claims ‘landmark’ study result that could widen heart drug’s use

    In a first-of-its-kind finding, Amgen’s PCSK9 drug protected heart health when tested as a “primary prevention” therapy, which could pave the way for access to a much broader population. 

    By • Oct. 2, 2025
  • U.S. President Donald Trump shakes hands with President of the European Commission Ursula von der Leyen as he announces a trade deal with the EU at Trump Turnberry golf club on July 27, 2025 .
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Pharma reshoring

    Key exemptions could limit impact of Trump’s pharmaceutical tariffs

    Carve-outs for generics, European exports and companies onshoring drug production will likely shield most branded drugs from the 100% levies Trump announced Thursday.

    By • Sept. 26, 2025
  • A child receives a standard immunization at Dr. Gary Kramer's pediatric office on September 15, 2025, in Coral Gables, Florida.
    Image attribution tooltip
    Joe Raedle / Staff via Getty Images
    Image attribution tooltip
    Deep Dive

    Disparity in vaccine access between states roils patients, providers

    Recent changes to federal guidance on COVID vaccinations have providers worried about what’s to come. “We have opened a door to not using science to guide care,” one physician said.

    By Susanna Vogel • Sept. 23, 2025
  • A person in business attire points while seated at a conference table with other people.
    Image attribution tooltip
    Elijah Nouvelage via Getty Images
    Image attribution tooltip
    Vaccines

    CDC panel, recast by RFK Jr., softens COVID vaccine recommendations

    After a tumultuous two-day meeting marked by confusion and missteps, an advisory committee endorsed guidelines that would urge people to discuss vaccination's benefits and risks with their physician.

    By , • Sept. 19, 2025
  • People in business attire speak while seated at a conference table.
    Image attribution tooltip
    Elijah Nouvelage via Getty Images
    Image attribution tooltip
    Vaccines

    CDC advisers postpone vote to delay some newborns’ hepatitis B shot

    Members of ACIP voted to table a planned vote on withholding some infants’ first hepatitis B vaccine dose, adding more confusion to an already muddied meeting.

    By • Sept. 19, 2025
  • A person in business attire speaks into a microphone while seated at a desk.
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip
    Vaccines

    Fired CDC director says RFK Jr. aims to change childhood vaccine schedule

    Susan Monarez told Senators at a hearing Wednesday that Robert F. Kennedy Jr. pushed her out for refusing to rubber-stamp changes.

    By • Sept. 17, 2025
  • People in business attire sit around a conference table.
    Image attribution tooltip
    Elijah Nouvelage / Stringer via Getty Images
    Image attribution tooltip
    Vaccines

    A key CDC panel meets today to discuss vaccines. Here’s what to know.

    The remade ACIP panel is set to vote today on recommendations for use of vaccines for measles and hepatitis B. They’ll meet again tomorrow to discuss COVID shots.

    By • Updated Sept. 15, 2025
  • Image of Johnson & Johnson's Inlexzo, a chemotherapy-eluted implant for treatment of bladder cancer.
    Image attribution tooltip
    Courtesy of Johnson & Johnson
    Image attribution tooltip

    FDA clears J&J’s drug-device combo for bladder cancer

    J&J executives have said they expect the therapy, Inlexzo, to become a future blockbuster and generate sales that significantly outstrip Wall Street forecasts.

    By • Sept. 10, 2025
  • A person in a blue sit sits behind a desk at a hearing.
    Image attribution tooltip
    Andrew Harnik via Getty Images
    Image attribution tooltip
    Trump administration

    At Senate hearing, lawmakers express dissatisfaction with RFK Jr.’s vaccine moves

    Robert F. Kennedy Jr. faced criticism Thursday even from Republicans over changes to federal vaccine policy as well as a leadership crisis at the CDC.

    By , • Sept. 4, 2025
  • Image of a brain in purple outline with red details.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Biohaven’s rare disease drug is ‘ready to ship on Day 1’ following FDA approval

    CEO Vlad Coric said the company has a patient hub, payer managers and a small sales force set up to ensure a successful launch of Vyglxia, a brain medicine that could be approved this year.

    By • Updated Sept. 4, 2025
  • The exterior of Ionis Pharmaceuticals' headquarters in Carlsbad, California.
    Image attribution tooltip
    Courtesy of Ionis Pharmaceuticals
    Image attribution tooltip

    Ionis looks to expand use of lipid-lowering drug after trial hits goal

    Tryngolza, the first wholly owned drug Ionis has launched, helped people with high triglyceride levels that aren’t genetically driven.

    By • Sept. 2, 2025